Oral Presentation MIN Spring Retreat 2023

The Vγ9Vδ2+ T cell receptor co-binds butyrophilins 2A1 and 3A1 (#11)

Tom S Fulford 1 , Caroline Soliman 1 , Rebecca G Castle 1 , Marc Rigau 1 2 , Zheng Ruan 1 , Olan Dolezal 3 , Shihan Li 1 , Samuel J Redmond 1 , Michael A Gorman 4 , Andrew Hammet 5 , Michael W Parker 4 , Tom S Peat 3 , Janet Newman 3 , Andreas Behren 6 , Nicholas A Gherardin 1 , Dale I Godfrey 1 , Adam P Uldrich 1
  1. Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia
  2. University of Bonn, Bonn, Germany
  3. Biomedical Manufacturing, Commonwealth Scientific and Industrial Research Organisation, Parkville, VIC, Australia
  4. Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia
  5. CSL Limited, Bio21 Institute, Parkville, VIC, Australia
  6. Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia

Whilst αβ T cell recognise MHC-Ag complexes for immunity, very little is known about the Ag-presenting elements of γδ T cells. Recently, butyrophilin (BTN) molecules have emerged as key regulators of γδ T cell immunity, however, the mechanism by which they activate the γδTCR is unknown. In humans, most circulating γδ T cells are phosphoantigen (pAg)-reactive Vγ9Vδ2+ T cells, which play a critical role in immunity to most bacterial and apicomplexan parasites infections as well as cancer. γδ T cells are also emerging as important mediators of anti-viral immunity to a broad range of viral infections, ranging from hepatitis B and C, cytomegalovirus, EBV and human immunodeficiency virus infections and respiratory infections, such influenza and SARS-CoV-2. Recent studies have shown BTN molecules are up-regulated by sensors of cellular stress and viral infection, AMP kinase and NLRC5 respectively, potentially co-ordinating Vγ9Vδ2+ T cell responses to virally infected cells.

 

To explore how BTNs co-ordinate γδ T cell immunity, we solved the crystal structure of Vγ9Vδ2+ TCR in complex with BTN member 2A1 (BTN2A1), revealing that BTN2A1 engages the side of the γδTCR. Intriguingly, we also found that a second ligand, namely BTN3A1, can bind the exposed apical surface of Vγ9Vδ2+ TCR alongside BTN2A1. However, BTN3A1 binding only occurred following cross-linking with an agonist anti-BTN3A1 mAb, or alternatively, following mutation of a negative regulatory residue, Lys53 of the TCR δ-chain. Indeed, we demonstrate that mutation of the Lys53 residue confers spontaneous reactivity of the γδ T cell to BTN2A1–BTN3A1 expressing cells.

 

Our findings reveal a new paradigm in immune activation, whereby a single γδTCR recognises two BTN molecules, the so-called ‘two-ligand, one-receptor’ model of immune activation, and offer a potential new avenue for treatment of viral infection.